The effects of add-back therapy with XXXX on @entity1868 uteri.

@entity1 @entity4396 @entity43013 @entity53 @entity11347 @entity1868 @entity2588
In this prospective, randomized, double-blind study, we evaluated the effects of @entity11347 therapy in association with preoperative @entity4396 agonist (GnRHa) therapy on the reduction of @entity1868 volume. Twenty @entity1 with @entity1868 uteri were divided into two groups. Group I was given monthly @entity43013 (3.75 mg every 28 days IM) treatment for six months. As for group II, @entity11347 was added on to this treatment. For all of the @entity1 , physical examinations, pelvic ultrasonography, and hormone analyses were carried out and the @entity1868 volume was measured by ultrasonography. The @entity1 were called every month and physical examination, ultrasonography and hormone analyses were repeated. Side-effects were recorded. The SPSS/PC 6.0 program was used for statistical analysis. Statistical significance was defined as a p < 0.05. The results are expressed as means +/- SD. While the average volume of @entity1868 was 72.97 +/- 68.5 cm3 in group I, 78.83 +/- 74.1 cm3 in group II before treatment; it was reduced to 29.91 +/- 27.8 cm3 in group I at the end of six months of treatment. Reductions of 59.6% in group I and 63.9% in group II were determined, however the difference was not statistically significant (p > 0.05). At the beginning the level of serum @entity53 was 65.4 +/- 22.3 pg/ml in group I which decreased to 37.2 +/- 4.2 pg/ml by the end of the first month. @entity2588 occurred in six @entity1 after the second injection and four @entity1 after the third injection in group I. Whereas the level of @entity53 was 60.9 +/- 19.5 pg/ml in group II at the beginning, it was reduced to 40.5 +/- 6.2 pg/ml by the end of the first month. @entity2588 occurred in four @entity1 after the second injection and four @entity1 after the third injection in group II. In group I the @entity1 had the problem of flushing (80%), vaginal dryness (50%), and night sweats (30%). In group II these rates were 30%, 20%, and 20%, respectively. @entity43013 is a GnRHa which has been found to be effective in reducing @entity1868 volume, but this effect could not be deactivated with @entity11347 . However, a decrease was observed in the side-effects resulting from hypoestrogenism.
